Tangram Therapeutics says Phase 1 trial of bleeding disorder drug TGM-148 is underway

• Tangram Therapeutics will present TGM-148 preclinical data at the American Society of Hematology annual meeting on December 14, 2026.
• The bleeding-disorder treatment enhanced clotting activity in impaired blood samples but had no effect in samples without the modeled deficiency.
• Repeat-dose testing in healthy nonhuman primates showed no thrombotic safety signals, with treatment well tolerated at the highest dose tested.
• A Phase 1 trial in healthy volunteers is underway, with initial data expected in 2027.
• Von Willebrand disease is the planned initial indication; the treatment is designed for four or fewer injections annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tangram Therapeutics plc published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.